Search clinical trials for: CML in chronic phase

Total 461873 results

Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
Novartis Pharmaceuticals

Completed

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Chronic Myeloid Leukemia

United Kingdom, Germany
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Novartis Pharmaceuticals

Completed

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Belgium, Hungary, Spain, Germany, Canada, Switzerland, Thailand, Korea, Republic of, United Kingdom, Italy, Austria, Sweden, France, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Completed

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia

United States
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Completed

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia, Chronic Phase

China
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | MDS (Myelodysplastic Syndrome) | CML (Chronic Myelogenous Leukemia) | AML (Acute Myelogenous Leukemia)

United States
Prof. Dr. Nikolas von Bubnoff
Novartis

Terminated

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years (DECLINE)

Chronic Myeloid Leukemia

Germany
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Onco Medical Consult GmbH

Completed

Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib (DasPAQT)

Myeloid Leukemia, Chronic, Chronic-Phase

Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Germany, Italy, Austria, Iraq, United States, Brazil, China, Malaysia, Netherlands
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Chronic Myeloid Leukemia

France, United States, Spain, Belgium, Singapore, Poland, Canada, Japan, United Kingdom, Taiwan, Hungary, Germany, Argentina, Russian Federation, Turkey, Colombia, Italy, South Africa, Brazil, Chile, China, Hong Kong, India, Korea, Republic... and more
Arbeitsgemeinschaft medikamentoese Tumortherapie
AOP Orphan Pharmaceuticals AG

Completed

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Chronic Phase Chronic Myeloid Leukemia

Austria
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Myelogenous Leukemia, Chronic

United States
EDDC (Experimental Drug Development Centre), A*STAR...
Chiltern International Inc.

Withdrawn

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

United States, Singapore
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206)

Leukemia

Italy
Rex Cancer Center, Raleigh, NC
Northwestern University

Terminated

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

Chronic Phase CML

United States
Rex Cancer Center, Raleigh, NC
Novartis Pharmaceuticals; Leap of Faith Technologies

Terminated

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib in PH+, BCR-, ABL+ CML Patients (CML0811)

Chronic Myeloid Leukemia

Italy
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
Dong-A ST Co., Ltd.
SeoulCRO

Terminated

A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients (IDEAL)

Chronic Myeloid Leukemia

Korea, Republic of
The University of Hong Kong

Unknown

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia

Leukemia, Myelogenous, Chronic Phase

Hong Kong
First Affiliated Hospital of Harbin Medical University

Unknown

Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients (HU)

Leukemia, Chronic Myeloid

China
Heidelberg University

Completed

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

Germany, Switzerland
Junmin Li

Suspended

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Chronic Myelogenous Leukemia

China
Newcastle University
Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaborators

Completed

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (SPIRIT2)

Myeloid Leukemia, Chronic, Chronic Phase

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genzyme, a Sanofi Company

Terminated

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (POE07-01)

Acute Myeloid Leukemia | Myeloproliferative Disorders | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Promyelocytic Leukemia | Chronic Myelogenous Leukemia

United States, Canada
Versailles Hospital

Completed

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (OPTIMIMATINIB)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Seoul National University Hospital
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib in CML-CP (ENESTKorea)

Chronic Myeloid Leukemia, Chronic Phase
Novartis Pharmaceuticals

Terminated

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (ENESTswift)

Philidelphia Positive Chronic Myeloid Leukaemia

Australia
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
University of Bonn
Pfizer; RWTH Aachen University; Ludwig-Maximilians - University of Munich; Heidelberg... and other collaborators

Unknown

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (BODO)

Chronic Myelogenous Leukaemia

Germany
Novartis Pharmaceuticals

Withdrawn

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (MACS1881)

Chronic Myeloid Leukemia (CML)

Brazil
Beth Israel Deaconess Medical Center
Amgen

Completed

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (MINI HEME)

AML | MDS | CLL | ALL | CML Chronic Phase, Accelerated Phase, or Blast Crisis | RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA | APLASTIC ANEMIA | MULTIPLE MYELOMA | MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more

Search clinical trials for: CML in chronic phase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations